PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCrisaborole
Eucrisa, Staquis(crisaborole)
Eucrisa, Staquis (crisaborole) is a small molecule pharmaceutical. Crisaborole was first approved as Eucrisa on 2016-12-14. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target 3',5'-cyclic-AMP phosphodiesterase 4B; cAMP-specific 3',5'-cyclic phosphodiesterase 4B, high affinity 3',5'-cyclic-AMP phosphodiesterase 7A; high affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A, and dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Eucrisa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Crisaborole
Tradename
Company
Number
Date
Products
EUCRISAAnacor PharmaceuticalsN-207695 RX2016-12-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
eucrisaNew Drug Application2024-01-16
staquisExport only2023-06-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atopic dermatitisEFO_0000274D003876L20
Agency Specific
FDA
EMA
Expiration
Code
CRISABOROLE, EUCRISA, ANACOR PHARMS INC
2026-04-03D-191
Patent Expiration
Patent
Expires
Flag
FDA Information
Crisaborole, Eucrisa, Anacor Pharms Inc
81686142030-01-20U-1932
80394512029-06-29DS, DP
85017122027-02-16U-1932
96820922027-02-16U-1932
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH06: Crisaborole
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L204577224
EczemaD004485HP_0000964L30.9———2—2
Seborrheic dermatitisD012628HP_0001051L21———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4034———7
Alopecia areataD000506EFO_0004192L63—1———1
Localized sclerodermaD012594EFO_1001361L94.0—1———1
VitiligoD014820EFO_0004208L80—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCrisaborole
INNcrisaborole
Description
Crisaborole is a member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. It has a role as a phosphodiesterase IV inhibitor, an antipsoriatic and a non-steroidal anti-inflammatory drug. It is a benzoxaborole, an aromatic ether and a nitrile.
Classification
Small molecule
Drug classboroles, boron compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
Identifiers
PDB—
CAS-ID906673-24-3
RxCUI—
ChEMBL IDCHEMBL484785
ChEBI ID—
PubChem CID44591583
DrugBankDB05219
UNII IDQ2R47HGR7P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PDE4B
PDE4B
PDE7A
PDE7A
PDE1A
PDE1A
Organism
Homo sapiens
Gene name
PDE4B
Gene synonyms
DPDE4
NCBI Gene ID
5142
Protein name
3',5'-cyclic-AMP phosphodiesterase 4B; cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Protein synonyms
cAMP-specific phosphodiesterase 4B, DPDE4, dunce-like phosphodiesterase E4, PDE32, phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)
Uniprot ID
Q5TEK6
Mouse ortholog
Pde4b (18578)
3',5'-cyclic-AMP phosphodiesterase 4B (Q9QXI7)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eucrisa – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 586 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,161 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use